Could a monthly IVIG infusion ease severe OCD in kids with PANS?
NCT ID NCT04609761
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a monthly dose of intravenous immunoglobulin (IVIG) for 6 months in 17 children aged 4–17 with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), a condition marked by sudden, severe OCD or food refusal. Researchers measured changes in symptom severity and daily functioning. Because it was a small, open-label trial (no placebo), the results are preliminary and need confirmation in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulin (IVIG, brand name Privigen)
- What this could lead to
- If it works, this could point toward a treatment for PANS, a condition with sudden severe OCD or eating restrictions in children.
- What could go wrong
- This is a small, early-phase trial with only 17 participants and no placebo group, so results may not be reliable or apply to all children. IVIG can cause side effects like headache, fever, or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANS PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gillberg Neuropsychiatry Centre
Gothenburg, 411 19, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.